

QUICK GUIDE

Cow's Milk Protein Allergy

Cow's Milk Allergy (CMA) affects 2-3% of infants in the UK.¹ This quick guide aims to highlight key differences between immunoglobulin E (IgE)- and non-IgE mediated CMA.

CMA Type	Timing of symptoms	Reproducibility	Symptoms			
			Skin	Gut	Respiratory	Other
IgE-Mediated	<ul style="list-style-type: none"> Develop within minutes to 1-2 hrs Resolve within 1-2 hrs; small number of patients have a secondary late reaction 	<ul style="list-style-type: none"> Baked milk may be tolerated Symptoms otherwise occur every time they are given cow's milk products 	<ul style="list-style-type: none"> Urticaria Angioedema Itching & erythema 	<ul style="list-style-type: none"> Oral puritis Vomiting Diarrhoea Abdominal pain 	<ul style="list-style-type: none"> Rhino-conjunctivitis 	<ul style="list-style-type: none"> Anaphylaxis (ABCD)*
Non-IgE-Mediated	<ul style="list-style-type: none"> Present 2-72 hours after ingestion 	<ul style="list-style-type: none"> Baked milk may be tolerated Symptoms otherwise occur every time they are given cow's milk products 	<ul style="list-style-type: none"> Itching & erythema Non-specific rashes Does not cause eczema, but can make eczema difficult to manage** 	<p>Upper gut</p> <ul style="list-style-type: none"> Vomiting Reflux <p>Lower gut</p> <ul style="list-style-type: none"> Frequent, loose stool Constipation Blood +/- mucous in the stool Perianal redness Unsettled, & cry for longer periods 	<ul style="list-style-type: none"> Nasal congestion 	<ul style="list-style-type: none"> Severe disease may cause height or weight impairment Possible food aversion/refusal which may contribute to growth issues

*ABCD = Airway (coughing, voice change, tongue swelling), Breathing (wheezing, difficulty in breathing), Conscious level/Circulation (dizziness, pale, tachycardia, hypotension, collapse), Deterioration (continued worsening of symptoms). **Removing the allergen should improve control alongside usual eczema management.

If IgE-CMA is suspected:

- Provide an allergy action plan⁴ and explain how allergic reactions present
- Prescribe antihistamines for mild to moderate reactions. Consider indications for prescribing adrenaline autoinjectors (AAI) (e.g., previous anaphylaxis or asthma^{5,6})
- Ensure AAI training is specific for the brand prescribed
- Give information on food labelling
- Breast feeding mothers do not need to remove cow's milk from their own diet unless this has clearly triggered a reaction. For those wanting formula, an extensively hydrolysed formula (EHF) should be prescribed; try amino acid formula (AAF) if there has been an anaphylactic reaction⁷
- Consider allergy testing²
- Refer to an allergy clinic²

If non-IgE CMA is suspected:

Breastfed infants

- Continued breast feeding should be encouraged
- Cow's milk should be removed from maternal diet for 2-4 weeks to see if symptoms resolve
- Mothers should have supplements containing 1000 mg calcium and 400 IU vitamin D
- 50% babies with Non IgE CMA will also have soya allergy³

Formula fed infants

- Prescribe an EHF; the majority of infants will tolerate EHF
- AAF should be given to those with growth restriction or multiple allergies⁷
- Symptoms may take 2-4 weeks to resolve. Allow sufficient time before switching to an AAF. If there is partial improvement after 2-4 weeks, then trial AAF⁷
- Each formula has slight differences. Some infant formulas containing probiotics may help relieve symptoms and promote tolerance acquisition⁸
- Initially prescribe 2 x 400g. Families should be warned that stools can turn green, and compliance may be an issue. Adding vanilla essence drops to the formula can help. Once the formula is tolerated, prescribe enough tins for the child's weight; see iMAP guidelines.
- Once diagnosis is confirmed, prescription formulas are usually continued until the child is 2 years old¹

Confirmation of Diagnosis

Without any diagnostic tests, a rechallenge is done to confirm continued exclusion of milk is needed. If the infant's symptoms have fully improved after 2-4 weeks, they should be retried on milk to confirm their symptoms return. Breast-feeding mothers should return to a normal diet. Formula fed infants should be tried on small amounts of cow's milk formula to see if their allergy symptoms return (see iMAP guidelines). The amount of milk given can be steadily increased if tolerated. If symptoms return, a definite diagnosis can be given.³

Ongoing Treatment

Once non-IgE CMA is confirmed, milk products should be excluded for six months and then reintroduced using the milk ladder (see iMAP guidelines). NICE recommends referral to a dietician. Infants with growth restriction should be referred to secondary care.²

Weaning

Weaning should not be put on hold for CMA. More guidance can be found in the BSACI Early Feeding Guidance.⁹ Infants should avoid cow's milk/animal milks and their products.

Prognosis

Approximately 2/3 of children with CMA can tolerate milk by the age of 5; approximately 1 in 20 will have an allergy that persists into adulthood.¹

References

1. Luyt D et al.; Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). *Clin Exp Allergy*. 2014;44(5):642-72.
2. National Institute for Health and Care Excellence. (2011). CG116.
3. Venter C et al. *Clin Transl Allergy*. 2017 Aug 23;7:26.
4. British Society for Allergy and Clinical Immunology (BSACI) Paediatric Allergy Action Plans.
5. National Institute for Health and Care Excellence. (2011). CG134.
6. Jones C. *Clin Exp Allergy*. 2018 Dec;48(12):1619-1620.
7. Venter C. *Clin Transl Allergy*. 2013 Jul 8;3(1):23.
8. Tan-Lim CSC, Esteban-Ipac NAR. *World Allergy Organ J*. 2018 Nov 6;11(1):25.
9. British Society for Allergy and Clinical Immunology (BSACI) Early Feeding Guidance.



Helen Evans-Howells

Dr Helen Evans-Howells is a GP and worked with the allergy team at the University Hospital of Southampton for over four years. She lectures extensively on the subject both nationally and internationally and was the Chair of the Primary Care Group of the British Society of Allergy and Clinical Immunology (BSACI) from 2017 to 2020. She now runs 'Dorset Allergy' - a private allergy clinic for adults and children in Bournemouth and Dorchester. Helen is now a trustee for the charity Anaphylaxis UK.

STOP the symptoms of CMA faster* and **START** reducing the risk of future allergic manifestations



NEW clinical study reinforces consistent superiority¹⁻⁷

>2X MORE INFANTS
returned to cow's milk
vs whey-based EHF^{1†}

57% FEWER INFANTS
developed allergic manifestations
vs whey-based EHF^{1‡}

Plus Nutramigen LGG® provides
99% AVERAGE CLINICAL EFFICACY^{8§}

Nutramigen LGG® is a food for special medical purposes for the dietary management of cow's milk allergy and must be used under medical supervision. Nutramigen LGG® is not recommended for premature and immunocompromised infants unless directed and supervised by a healthcare professional.

IMPORTANT NOTICE: Breastfeeding is best for babies. The decision to discontinue breastfeeding may be difficult to reverse and the introduction of partial bottle-feeding may reduce breast milk supply. The financial benefits of breastfeeding should be considered before bottle-feeding is initiated. Failure to follow preparation instructions carefully may be harmful to the health of the baby. Parents should always be advised by an independent healthcare professional regarding infant feeding. Products of Mead Johnson must be used under medical supervision.

* Compared to extensively hydrolysed formula (EHF) without LGG®. † After 12 months of dietary management. ‡ Allergic manifestations during a period of 36 months included eczema, urticaria, asthma, and rhinoconjunctivitis. § Calculated using data on allergic reactions after oral food challenge with an EHF from Table 3 of Dupont *et al.* Studied before the addition of LGG®.

References: 1. Nocerino R, et al. *J Pediatr.* 2021;S0022-3476(21)00093-7. 2. Canani RB et al. *Clin Immunol.* 2017;139(6):1906-1913. 3. Baldassarre ME, et al. *J Pediatr.* 2010;156:397-401. 4. Lothe L et al. *Pediatrics.* 1989; 83:262-266. 5. Nermes M et al. *Clin Exp Allergy.* 2011;41:370-377. 6. Canani RB, et al. *J Pediatr.* 2013;163:771-777. 7. Canani RB, et al. *J Allergy Clin Immunol.* 2012;129:580-582. 8. Dupont C et al. *Br J Nutr.* 2012;107(3):325-338.

Trademark of Mead Johnson & Company, LLC. © 2021 Mead Johnson & Company, LLC. All rights reserved. LGG® is a registered trademark of Chr. Hansen A/S. Date of Preparation: October 2021 | RB-M-55051



Help **STOP** the domino effect^{1,2}